# A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects

> **NCT00306189** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 212 (actual)

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** 100 mg AMG 162
- **DRUG:** 60 mg AMG 162
- **DRUG:** 14 mg AMG 162
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00306189
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2007-06
- **Final completion:** 2007-11
- **Target enrollment:** 212 (ACTUAL)
- **Last updated:** 2013-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00306189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00306189, "A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00306189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*